{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:28:55Z","timestamp":1787066935983,"version":"build-2736575974"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40268-020-00333-0","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T14:03:09Z","timestamp":1608213789000},"page":"9-27","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-1149","authenticated-orcid":false,"given":"Fiona","family":"Marra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise J.","family":"Smolders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"El-Sherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Sommerville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catia","family":"Marzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Siccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Back","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"333_CR1","doi-asserted-by":"crossref","unstructured":"Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephro., 2020.","DOI":"10.1038\/s41581-020-0284-7"},{"issue":"5","key":"333_CR2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S2468-1253(20)30057-1","volume":"5","author":"C Zhang","year":"2020","unstructured":"Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"333_CR3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/liv.13682","volume":"38","author":"P Marcellin","year":"2018","unstructured":"Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018;38(Suppl 1):2\u20136.","journal-title":"Liver Int"},{"key":"333_CR4","unstructured":"Qi X. COVID-19 in patients with pre-existing cirrhosis (COVID-Cirrhosis-CHESS2002): a multicentre observational study. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04329559."},{"issue":"10223","key":"333_CR5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395(10223):497\u2013506.","journal-title":"China. Lancet"},{"issue":"10223","key":"333_CR6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507\u201313.","journal-title":"Lancet"},{"key":"333_CR7","doi-asserted-by":"crossref","unstructured":"Fan Z, et al. Clinical features of COVID-19-related liver damage. Clin Gastroenterol Hepatol. 2020.","DOI":"10.1101\/2020.02.26.20026971"},{"issue":"3","key":"333_CR8","doi-asserted-by":"crossref","first-page":"100113","DOI":"10.1016\/j.jhepr.2020.100113","volume":"2","author":"T Boettler","year":"2020","unstructured":"Boettler T, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113.","journal-title":"JHEP Rep"},{"key":"333_CR9","doi-asserted-by":"crossref","unstructured":"Phipps MM, et al. Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large US Cohort. Hepatology. 2020.","DOI":"10.1002\/hep.31404"},{"key":"333_CR10","doi-asserted-by":"crossref","unstructured":"Fu Y, et al. Clinical features of COVID-19-infected patients with elevated liver biochemistries: a multicenter, retrospective study. Hepatology, 2020.","DOI":"10.1002\/hep.31446"},{"issue":"9","key":"333_CR11","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/CM9.0000000000000775","volume":"133","author":"W Liu","year":"2020","unstructured":"Liu W, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020;133(9):1032\u20138.","journal-title":"Chin Med J (Engl)"},{"key":"333_CR12","doi-asserted-by":"crossref","unstructured":"Collaborative TO, Williamson EW, Bhaskaran AJ, Bacon KJ, Bates S, Morton C, Curtis CE, Mehrkar HJ, Evans A, Inglesby D, Cockburn P, Mcdonald J, MacKenna HI, Tomlinson B, Douglas L, Rentsch IJ, Mathur CT, Wong R, Grieve A, Harrison R, Forbes D, Schultze H, Croker A, Parry RT, Hester J, Harper F, Perera S, Evans R, Smeeth S, Goldacre GB. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. 2020.","DOI":"10.1038\/s41586-020-2521-4"},{"issue":"10225","key":"333_CR13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GCKD Collaboration","year":"2020","unstructured":"Collaboration GCKD. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709\u201333.","journal-title":"Lancet"},{"key":"333_CR14","doi-asserted-by":"crossref","unstructured":"Goldfarb DS, et al. Impending shortages of kidney replacement therapy for COVID-19 patients. Clin J Am Soc Nephrol. 2020.","DOI":"10.2215\/CJN.05180420"},{"key":"333_CR15","doi-asserted-by":"crossref","unstructured":"Wang D, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020.","DOI":"10.1001\/jama.2020.1585"},{"issue":"2","key":"333_CR16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1515\/dx-2020-0046","volume":"7","author":"S Aggarwal","year":"2020","unstructured":"Aggarwal S, et al. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis (Berl). 2020;7(2):91\u20136.","journal-title":"Diagnosis (Berl)"},{"key":"333_CR17","unstructured":"Volunteers A-N, et al. Caution on kidney dysfunctions of COVID-19 patients."},{"key":"333_CR18","doi-asserted-by":"crossref","unstructured":"Pei G, et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J Am Soc Nephrol. 2020.","DOI":"10.1681\/ASN.2020030276"},{"key":"333_CR19","unstructured":"Liverpool, U.o. COVID 19 Drug Interactions. 8\/5\/20 8\/5\/20]. https:\/\/www.covid19-druginteractions.org\/."},{"key":"333_CR20","unstructured":"Global Coronavirus COVID-19 Clinical Trial Tracker. 10\/04\/2020]. hhttps:\/\/covid19-trials.com\/."},{"key":"333_CR21","doi-asserted-by":"crossref","unstructured":"Zeitlinger MAK, Birgit CP, Br\u00fcggemann R, De Cock, Pieter, Felton, Timothy, Hites, Maya, Le, Jennifer, Luque, Sonia, MacGowan, Alasdair, Marriott, Deborah, Muller, Anouk E, Nadrah, Kristina, Paterson, David, Standing, Joseph F, Telles JP, W\u00f6lfl-Duchek, M, Thy MR, Jason A. Pharmacokinetics-pharmacodynamics of antiviral agents used to treat SARS-CoV-2 and their potential interaction with drugs and other supportive measures: a comprehensive review by the PK\/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. 2020. p. 178.","DOI":"10.2139\/ssrn.3561236"},{"key":"333_CR22","doi-asserted-by":"crossref","DOI":"10.1201\/9780429460418","volume-title":"The Renal Drug Handbook: The Ultimate Prescribing Guide for Renal Practitioners","author":"C Ashley","year":"2018","unstructured":"Ashley C, Dunleavy A. The Renal Drug Handbook: The Ultimate Prescribing Guide for Renal Practitioners, vol. 5. Milton Park: Taylor & Francis Ltd.; 2018."},{"key":"333_CR23","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (U.S.), LiverTox : clinical and research information on drug-induced liver injury. 2012, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD). p. 1 online resource (1 PDF file)"},{"key":"333_CR24","unstructured":"Truven Health Analytics Inc. and Micromedex Inc., Micromedex gateway. 2011, Truven Health Analytics."},{"key":"333_CR25","unstructured":"Aspen. Dexamethasone 2mg tablets, Summary of Product Characteristics. 2020. https:\/\/www.medicines.org.uk\/emc\/product\/5411\/smpc. Accessed 10 Nov 2020."},{"key":"333_CR26","unstructured":"Horby P. Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial. 2020.\u00a0. 8 May 2020]. www.recoverytrial.net. Accessed 10 Nov 2020."},{"issue":"3","key":"333_CR27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1210\/jcem-63-3-741","volume":"63","author":"RJ Workman","year":"1986","unstructured":"Workman RJ, Vaughn WK, Stone WJ. Dexamethasone suppression testing in chronic renal failure: pharmacokinetics of dexamethasone and demonstration of a normal hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab. 1986;63(3):741\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"333_CR28","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1210\/jcem-60-5-848","volume":"60","author":"S Kawai","year":"1985","unstructured":"Kawai S, Ichikawa Y, Homma M. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. J Clin Endocrinol Metab. 1985;60(5):848\u201354.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"333_CR29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/106002809002400301","volume":"24","author":"DM Cummings","year":"1990","unstructured":"Cummings DM, et al. Characterization of dexamethasone binding in normal and uremic human serum. DICP. 1990;24(3):229\u201331.","journal-title":"DICP"},{"issue":"3","key":"333_CR30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11864-003-0025-8","volume":"4","author":"SR Pandit","year":"2003","unstructured":"Pandit SR, Vesole DH. Management of renal dysfunction in multiple myeloma. Curr Treat Options Oncol. 2003;4(3):239\u201346.","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"333_CR31","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.3892\/etm.2016.3720","volume":"12","author":"B Zhao","year":"2016","unstructured":"Zhao B, et al. Evaluation of the efficacy of steroid therapy on acute liver failure. Exp Ther Med. 2016;12(5):3121\u20139.","journal-title":"Exp Ther Med"},{"issue":"9902","key":"333_CR32","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0140-6736(12)62163-1","volume":"382","author":"MA Heneghan","year":"2013","unstructured":"Heneghan MA, et al. Autoimmune hepatitis. Lancet. 2013;382(9902):1433\u201344.","journal-title":"Lancet"},{"issue":"4","key":"333_CR33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0960-0760(97)00038-1","volume":"62","author":"ES Tomlinson","year":"1997","unstructured":"Tomlinson ES, et al. Dexamethasone metabolism in vitro: species differences. J Steroid Biochem Mol Biol. 1997;62(4):345\u201352.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"333_CR34","unstructured":"REYATAZ (atazanavir) capsules, US Prescribing Information. BMS."},{"key":"333_CR35","unstructured":"Reyataz 300mg Hard Capsules, Summary of Product Characteristics. Last updated on emc: 25 Feb 2019, BMS."},{"key":"333_CR36","unstructured":"EACS Guidelines version 10.0. November 2019."},{"issue":"4","key":"333_CR37","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/ndt\/gfh684","volume":"20","author":"H Izzedine","year":"2005","unstructured":"Izzedine H, et al. Atazanavir: a novel inhibitor of HIV-protease in haemodialysis. Nephrol Dial Transplant. 2005;20(4):852\u20133.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"333_CR38","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/jac\/dkn383","volume":"62","author":"G Guaraldi","year":"2008","unstructured":"Guaraldi G, et al. A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. J Antimicrob Chemother. 2008;62(6):1356\u201364.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"333_CR39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s15010-008-8025-z","volume":"37","author":"G Guaraldi","year":"2009","unstructured":"Guaraldi G, et al. Efficacy and safety of atazanavir in patients with end-stage liver disease. Infection. 2009;37(3):250\u20135.","journal-title":"Infection"},{"issue":"3","key":"333_CR40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2125.2005.02413.x","volume":"60","author":"JE Ray","year":"2005","unstructured":"Ray JE, et al. Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol. 2005;60(3):291\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"333_CR41","unstructured":"Kaletra 200 mg\/50 mg film-coated tablets summary of product characteristics. 2019: AbbVie Ltd."},{"issue":"19","key":"333_CR42","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787\u201399.","journal-title":"N Engl J Med"},{"key":"333_CR43","unstructured":"Kaletra, US Prescribing information. 2019, Abbvie."},{"issue":"15","key":"333_CR44","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/QAD.0b013e32830e011f","volume":"22","author":"SK Gupta","year":"2008","unstructured":"Gupta SK, et al. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir\/ritonavir in HIV-infected persons requiring hemodialysis. AIDS. 2008;22(15):1919\u201327.","journal-title":"AIDS"},{"issue":"3","key":"333_CR45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0091270005284853","volume":"46","author":"JZ Peng","year":"2006","unstructured":"Peng JZ, et al. Pharmacokinetics of lopinavir\/ritonavir in HIV\/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol. 2006;46(3):265\u201374.","journal-title":"J Clin Pharmacol"},{"key":"333_CR46","unstructured":"(EMA) E.MA. Summary on compassionate use: Remdesivir, Gilead. 2020 12\/5\/2020]. https:\/\/www.ema.europa.eu\/en\/documents\/other\/summary-compassionate-use-remdesivir-gilead_en.pdf. Accessed 10 Nov 2020."},{"key":"333_CR47","unstructured":"Emergency Use Authorisation (EUA) of remdsivir (GS-5734\u2122). 2020, Gilead."},{"key":"333_CR48","unstructured":"Gilead. Veklury (Remdesivir) 100mg concentrate for solution. 2020. www.medicines.org.uk\/emc\/product\/11596\/smpc. Accessed 10 Nov 2020."},{"key":"333_CR49","unstructured":"Grein J, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020."},{"issue":"6","key":"333_CR50","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jcph.1077","volume":"58","author":"RK Hoover","year":"2018","unstructured":"Hoover RK, et al. Clinical Pharmacokinetics of Sulfobutylether-\u03b2-Cyclodextrin in Patients With Varying Degrees of Renal Impairment. J Clin Pharmacol. 2018;58(6):814\u201322.","journal-title":"J Clin Pharmacol"},{"key":"333_CR51","doi-asserted-by":"crossref","unstructured":"Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV Infection. Clin Pharmacol Ther. 2020.","DOI":"10.1002\/cpt.1844"},{"key":"333_CR52","unstructured":"Avigan (favipiravir) Tablet 200 mg. 2011, Toyama Chemical Co., Ltd."},{"key":"333_CR53","doi-asserted-by":"crossref","unstructured":"Chen CZY. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. 2020.","DOI":"10.1101\/2020.03.17.20037432"},{"issue":"2","key":"333_CR54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1620\/tjem.251.87","volume":"251","author":"E Mishima","year":"2020","unstructured":"Mishima E, et al. Uric Acid Elevation by Favipiravir, an Antiviral Drug. Tohoku J Exp Med. 2020;251(2):87\u201390.","journal-title":"Tohoku J Exp Med"},{"key":"333_CR55","unstructured":"Preston R. Pharmacokinetics of favipiravir in volunteers with hepatic impairment. 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01419457."},{"key":"333_CR56","unstructured":"Fujifilm Pharmaceuticals U.S.A., I. Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04358549."},{"key":"333_CR57","doi-asserted-by":"crossref","unstructured":"Mehra, M., et al., Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020.","DOI":"10.1016\/S0140-6736(20)31180-6"},{"key":"333_CR58","doi-asserted-by":"crossref","unstructured":"Gendrot M, et al. Chloroquine as a prophylactic agent against COVID-19? Int J Antimicrob Agents. 2020;55(6):105980","DOI":"10.1016\/j.ijantimicag.2020.105980"},{"key":"333_CR59","doi-asserted-by":"crossref","unstructured":"Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020.","DOI":"10.1093\/jac\/dkaa114"},{"key":"333_CR60","unstructured":"Bonten M. Randomised, embedded, multi-factorial, adaptive platform trial for community acquired pneumonia (REMAP-CAP) trial. 2020 8 May 2020]. https:\/\/www.remapcap.org\/. Accessed 10 Nov 2020."},{"issue":"8","key":"333_CR61","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/art.39194","volume":"67","author":"M Jallouli","year":"2015","unstructured":"Jallouli M, et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(8):2176\u201384.","journal-title":"Arthritis Rheumatol"},{"key":"333_CR62","unstructured":"Plaquenil Hydroxychloroquine Sulfate Tablets US Prescribing Information. 2017."},{"issue":"5","key":"333_CR63","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/0961203313476361","volume":"22","author":"JY Lee","year":"2013","unstructured":"Lee JY, et al. Factors associated with blood hydroxychloroquine level in lupus patients: renal function could be important. Lupus. 2013;22(5):541\u20132.","journal-title":"Lupus"},{"key":"333_CR64","unstructured":"Plaquenil-Hydroxychloroquine sulfate 200mg Film-coated Tablets, Summary of Product Characteristics. 2020, Zentiva."},{"key":"333_CR65","volume-title":"Therapeutic drugs","author":"C Dollery","year":"1999","unstructured":"Dollery C. Therapeutic drugs. 2nd ed. London: Churchill Livingstone; 1999.","edition":"2"},{"issue":"1A","key":"333_CR66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","volume":"75","author":"EW McChesney","year":"1983","unstructured":"McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med. 1983;75(1A):11\u20138.","journal-title":"Am J Med"},{"issue":"6","key":"333_CR67","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","volume":"27","author":"SE Tett","year":"1989","unstructured":"Tett SE, et al. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27(6):771\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"333_CR68","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jac\/dkg319","volume":"52","author":"DC Warhurst","year":"2003","unstructured":"Warhurst DC, et al. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J Antimicrob Chemother. 2003;52(2):188\u201393.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"333_CR69","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762\u201384.","journal-title":"Arthritis Rheum"},{"key":"333_CR70","unstructured":"FDA. Fact sheet for health care providers. Emergency use Authorisation (EUA) of hydroxychloroquine sulfate supplied supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients. 2020, U.S. Food and Drug Administration (FDA)."},{"key":"333_CR71","unstructured":"Zentiva. Azithromycin 250mg capsules, Summary of Product Characteristics. 2020. https:\/\/www.medicines.org.uk\/emc\/product\/8663\/smpc."},{"key":"333_CR72","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jac\/31.suppl_E.57","volume":"31 Suppl E","author":"T Mazzei","year":"1993","unstructured":"Mazzei T, et al. Pharmacokinetics of azithromycin in patients with impaired hepatic function. J Antimicrob Chemother. 1993; 31 Suppl E: 57\u201363.","journal-title":"J Antimicrob Chemother"},{"key":"333_CR73","unstructured":"Kong, U.o.H. Lopinavir\/ritonavir, ribavirin and IFN-beta combination for nCoV treatment. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04276688"},{"key":"333_CR74","doi-asserted-by":"crossref","unstructured":"Khalili JS, et al. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol. 2020.","DOI":"10.1002\/jmv.25798"},{"key":"333_CR75","unstructured":"Rebetol 200 mg hard capsules Summary of Product Characteristics. 2019. https:\/\/www.medicines.org.uk\/emc\/product\/3832\/smpc."},{"key":"333_CR76","unstructured":"Roche. COPEGUS\u00ae (ribavirin) Tablets, US Prescribing Information. Accessed 12\/5\/2020]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021511s023lbl.pdf."},{"issue":"20","key":"333_CR77","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1001\/jama.290.20.2663","volume":"290","author":"WM Wong","year":"2003","unstructured":"Wong WM, et al. Temporal patterns of hepatic dysfunction and disease severity in patients with SARS. JAMA. 2003;290(20):2663\u20135.","journal-title":"JAMA"},{"issue":"10","key":"333_CR78","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2165\/00002018-200427100-00005","volume":"27","author":"P Rieckmann","year":"2004","unstructured":"Rieckmann P, et al. Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis. Drug Saf. 2004;27(10):745\u201356.","journal-title":"Drug Saf"},{"issue":"11","key":"333_CR79","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00002018-200326110-00006","volume":"26","author":"GS Francis","year":"2003","unstructured":"Francis GS, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf. 2003;26(11):815\u201327.","journal-title":"Drug Saf"},{"key":"333_CR80","unstructured":"Rebif 22 micrograms solution for injection in cartridge. 2020, Merck."},{"key":"333_CR81","unstructured":"Rebif\u00a0US Prescribing Information. 2014: Pfizer."},{"key":"333_CR82","unstructured":"A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia (COVACTA). 2020 30\/03\/2020 25\/03\/2020]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04320615"},{"key":"333_CR83","unstructured":"Actemra (tocilizumab) injection, for intravenous or subcutaneous use, US Prescribing Information. Genentech Inc. Roche."},{"key":"333_CR84","unstructured":"RoActemra 20mg\/ml Concentrate for Solution for Infusion Summary of Product Characteristics. 2019. https:\/\/www.medicines.org.uk\/emc\/product\/6673\/smpc. Accessed 10 Nov 2020."},{"issue":"11","key":"333_CR85","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40262-015-0296-9","volume":"54","author":"D Ternant","year":"2015","unstructured":"Ternant D, et al. Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis. Clin Pharmacokinet. 2015;54(11):1107\u201323.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"333_CR86","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/art.40176","volume":"69","author":"MC Genovese","year":"2017","unstructured":"Genovese MC, et al. Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis. Arthritis Rheumatol. 2017;69(9):1751\u201361.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"333_CR87","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/cpt.1765","volume":"107","author":"Q Sun","year":"2020","unstructured":"Sun Q, et al. Does hepatic impairment affect the exposure of monoclonal antibodies? Clin Pharmacol Ther. 2020;107(5):1256\u201362.","journal-title":"Clin Pharmacol Ther"},{"key":"333_CR88","unstructured":"Kineret (Anakinra)100 mg solution for injection in a pre-filled syringe. 2019, Swedish Orphan Biovitrum Ltd."},{"key":"333_CR89","unstructured":"Kineret\u00ae (anakinra) for injection, for subcutaneous use. US Prescribing Information. Swedish Orphan Biovitrum AB."},{"key":"333_CR90","unstructured":"Delaporte, A. Treatment of COVID-19 patients with anti-interleukin drugs (COV-AID). 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04330638."},{"key":"333_CR91","doi-asserted-by":"crossref","unstructured":"Cavalli G, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020.","DOI":"10.1016\/S2665-9913(20)30127-2"},{"issue":"1","key":"333_CR92","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0009-9236(03)00094-8","volume":"74","author":"BB Yang","year":"2003","unstructured":"Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. 2003;74(1):85\u201394.","journal-title":"Clin Pharmacol Ther"},{"key":"333_CR93","unstructured":"Pinedo M, Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 Infection (SARCOVID) (SARCOVID). 2020."},{"key":"333_CR94","unstructured":"Branch-Elliman W. Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design. 2020 .https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04359901."},{"key":"333_CR95","unstructured":"Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19. 2020; Available from"},{"key":"333_CR96","unstructured":"Kevzara (Sarilumab) 150 mg solution for injection in pre-filled syringe. 2020; https:\/\/www.medicines.org.uk\/emc\/product\/762\/smpc. Accessed 10 Nov 2020."},{"issue":"2","key":"333_CR97","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/rheumatology\/kez265","volume":"59","author":"R Fleischmann","year":"2020","unstructured":"Fleischmann R, et al. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years\u2019 follow-up. Rheumatology (Oxford). 2020;59(2):292\u2013302.","journal-title":"Rheumatology (Oxford)"},{"key":"333_CR98","first-page":"519526","volume":"2011","author":"DN Amarapurkar","year":"2011","unstructured":"Amarapurkar DN. Prescribing medications in patients with decompensated liver cirrhosis. Int J Hepatol. 2011;2011:519526.","journal-title":"Int J Hepatol"},{"issue":"6","key":"333_CR99","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/psp4.39","volume":"4","author":"R Li","year":"2015","unstructured":"Li R, Barton HA, Maurer TS. A mechanistic pharmacokinetic model for liver transporter substrates under liver cirrhosis conditions. CPT Pharmacometr Syst Pharmacol. 2015;4(6):338\u201349.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"6","key":"333_CR100","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s13318-017-0418-x","volume":"42","author":"SJ Rhee","year":"2017","unstructured":"Rhee SJ, et al. Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal\/Hepatic-Impaired Young Adults and Elderly Populations. Eur J Drug Metab Pharmacokinet. 2017;42(6):973\u201380.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"333_CR101","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00003088-199834010-00002","volume":"34","author":"BM Power","year":"1998","unstructured":"Power BM, et al. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet. 1998;34(1):25\u201356.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"333_CR102","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","volume":"44","author":"D Czock","year":"2005","unstructured":"Czock D, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61\u201398.","journal-title":"Clin Pharmacokinet"},{"key":"333_CR103","unstructured":"FDA. Decadron (dexamethasone) tablets 2mg. US Prescribing Information. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/11664slr062_decadron_lbl.pdf. Accessed 10 Nov 2020."},{"issue":"Database issue","key":"333_CR104","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"DS Wishart","year":"2006","unstructured":"Wishart DS, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34(Database issue):D668\u201372.","journal-title":"Nucleic Acids Res"},{"key":"333_CR105","unstructured":"Avonex US Prescribing Information. 2019: Biogen Inc."},{"key":"333_CR106","unstructured":"Avonex 30 \u00b5g\/0.5 mL solution for injection Summary of Product Characteristics. 2019: Biogen Idec Ltd."},{"issue":"12","key":"333_CR107","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1517\/17425255.2015.1094055","volume":"11","author":"H Hegen","year":"2015","unstructured":"Hegen H, Auer M, Deisenhammer F. Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-\u03b2. Expert Opin Drug Metab Toxicol. 2015;11(12):1803\u201319.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"333_CR108","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/089686080102100407","volume":"21","author":"JR Kent","year":"2001","unstructured":"Kent JR, Almond MK, Dhillon S. Azithromycin: an assessment of its pharmacokinetics and therapeutic potential in CAPD. Perit Dial Int. 2001;21(4):372\u20137.","journal-title":"Perit Dial Int"},{"issue":"5","key":"333_CR109","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00002030-200203290-00006","volume":"16","author":"N Alatrakchi","year":"2002","unstructured":"Alatrakchi N, et al. Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. AIDS. 2002;16(5):713\u20137.","journal-title":"AIDS"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00333-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-020-00333-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00333-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T07:26:17Z","timestamp":1724052377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-020-00333-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1007\/s40268-020-00333-0","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,17]]},"assertion":[{"value":"26 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AB received research grant or personal fees from Abbvie and Gilead outside the submitted work. CM received support from the Adolf and Mary-Mil foundation. DBa received grants from AbbVie, Gilead, Novartis, BHIVA, and EACS during the conduct of the review and grants from Merck and ViiV outside the submitted work. FM received research grant or personal fees from Abbvie, Gilead, Janssen, MSD and ViiV outside the submitted work. KD received educational support from Gilead outside the submitted work. SK received grants from Abbvie, Gilead, Novartis, BHIVA and EACS during the conduct of the review and research grants and speakers\u2019 honoraria from ViiV, Gilead and AbbVie outside the submitted work.ES, DBu, AS, OES, MS and SG declare no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation and writing of this review received no direct funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"FM conceived of the study. FM and ES performed the literature review. FM, ES, AB, AS, KD, CM, OES and DBa, SK and MS interpreted the data, FM and ES compiled the tables, FM and ES wrote the manuscript, and all authors revised the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}